Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
Saved in:
| Title: | Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. |
|---|---|
| Authors: | Blauvelt, Andrew1 (AUTHOR) ablauvelt@oregonmedicalresearch.com, Lomaga, Mark2 (AUTHOR), Burge, Russel3,4 (AUTHOR), Zhu, Baojin3 (AUTHOR), Shen, Wei3 (AUTHOR), Shrom, David3 (AUTHOR), Dossenbach, Martin5 (AUTHOR), Pinter, Andreas6 (AUTHOR) |
| Source: | Journal of Dermatological Treatment. Mar2020, Vol. 31 Issue 2, p141-146. 6p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 141275565 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Blauvelt%2C+Andrew%22">Blauvelt, Andrew</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> ablauvelt@oregonmedicalresearch.com</i><br /><searchLink fieldCode="AR" term="%22Lomaga%2C+Mark%22">Lomaga, Mark</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Burge%2C+Russel%22">Burge, Russel</searchLink><relatesTo>3,4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhu%2C+Baojin%22">Zhu, Baojin</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shen%2C+Wei%22">Shen, Wei</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shrom%2C+David%22">Shrom, David</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dossenbach%2C+Martin%22">Dossenbach, Martin</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pinter%2C+Andreas%22">Pinter, Andreas</searchLink><relatesTo>6</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Journal+of+Dermatological+Treatment%22">Journal of Dermatological Treatment</searchLink>. Mar2020, Vol. 31 Issue 2, p141-146. 6p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=141275565 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/09546634.2019.1587146 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 6 StartPage: 141 Titles: – TitleFull: Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Blauvelt, Andrew – PersonEntity: Name: NameFull: Lomaga, Mark – PersonEntity: Name: NameFull: Burge, Russel – PersonEntity: Name: NameFull: Zhu, Baojin – PersonEntity: Name: NameFull: Shen, Wei – PersonEntity: Name: NameFull: Shrom, David – PersonEntity: Name: NameFull: Dossenbach, Martin – PersonEntity: Name: NameFull: Pinter, Andreas IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: Mar2020 Type: published Y: 2020 Identifiers: – Type: issn-print Value: 09546634 Numbering: – Type: volume Value: 31 – Type: issue Value: 2 Titles: – TitleFull: Journal of Dermatological Treatment Type: main |
| ResultId | 1 |
